B-MS' Nivolumab Impresses in Phase II Lung Cancer Trial
Friday, October 31, 2014
Source: Pharma Times Digital
Bristol-Myers Squibb watched its stock climb 9% as investors rubbed their hands together on news that its key PD-1 checkpoint inhibitor Opdivo (nivolumab) turned in an impressive performance in patients with advanced squamous cell lung cancer.
The company assessed the drug as a single agent in a Phase II trial involving patients with the disease who progressed after at least two prior systemic treatments.